EUVIMEDEUVIMED entdecken
Crossref

Sialic Acid‐Functionalized Pyroptosis Nanotuner for Epigenetic Regulation and Enhanced Cancer Immunotherapy

Jiahao Hu, Yuchan You, Luwen Zhu, Jucong Zhang, Yanling Song, Jingyi Lu, Xinyi Xu, Xiaochuan Wu, Xiajie Huang, Xiaoling Xu, Yongzhong Du iD

Small · 2024

DOI: 10.1002/smll.202306905 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, 2024. Verfasst von Jiahao Hu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, 866 Yu-Hang-Tang Road, Hangzhou, 310058, China. Hauptthemen laut MEDLINE: Pyroptosis, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 51 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The efficacy of immune checkpoint blockade (ICB) in promoting an immune response against tumors still encounters challenges such as low response rates and off‐target effects. Pyroptosis, an immunogenic cell death (ICD) mechanism, holds the potential to overcome the limitations of ICB by activating and recruiting immune cells. However, the expression of the pyroptosis‐related protein Gasdermin‐E(GSDME) in some tumors is limited due to mRNA methylation. To overcome this obstacle, sialic acid‐functionalized liposomes coloaded with decitabine, a demethylation drug, and triclabendazole, a pyroptosis‐inducing drug are developed. This nanosystem primarily accumulates at tumor sites via sialic acid and the Siglec receptor, elevating liposome accumulation in tumors up to 3.84‐fold at 24 h and leading to the upregulation of pyroptosis‐related proteins and caspase‐3/GSDME‐dependent pyroptosis. Consequently, it facilitates the infiltration of CD8 + T cells into the tumor microenvironment and enhances the efficacy of ICB therapy. The tumor inhibition rate of the treatment group is 89.1% at 21 days. This study highlights the potential of sialic acid‐functionalized pyroptosis nanotuners as a promising approach for improving the efficacy of ICB therapy in tumors with low GSDME expression through epigenetic alteration and ICD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyroptosisNeoplasmsHumansN-Acetylneuraminic AcidCD8-Positive T-LymphocytesEpigenesis, GeneticImmunotherapyLiposomesTumor Microenvironment

Stichwörter der Autor:innen

cancer immunotherapycombination therapyepigeneticspyroptosistumor targeting

Substanzen

N-Acetylneuraminic AcidLiposomes

Autor:innen und Institutionen

  • Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, 866 Yu-Hang-Tang Road, Hangzhou, 310058, China.
  • Shulan International Medical College, Zhejiang Shuren University, 8 Shuren Street, Hangzhou, 310015, China.
  • Innovation Center of Translational Pharmacy, Jinhua Institute of Zhejiang University, Jinhua, 321299, China.

ORCID-Profile: Yongzhong Du

Zitieren

APA

Hu, J., You, Y., Zhu, L., Zhang, J., Song, Y., Lu, J., Xu, X., Wu, X., Huang, X., Xu, X., & Du, Y. (2024). Sialic Acid‐Functionalized Pyroptosis Nanotuner for Epigenetic Regulation and Enhanced Cancer Immunotherapy. Small. https://doi.org/10.1002/smll.202306905

Vancouver

Hu J, You Y, Zhu L, Zhang J, Song Y, Lu J, et al. Sialic Acid‐Functionalized Pyroptosis Nanotuner for Epigenetic Regulation and Enhanced Cancer Immunotherapy. Small. 2024. doi:10.1002/smll.202306905

BibTeX
@article{Hu2024,
  author = {Hu, Jiahao and You, Yuchan and Zhu, Luwen and Zhang, Jucong and Song, Yanling and Lu, Jingyi and Xu, Xinyi and Wu, Xiaochuan and Huang, Xiajie and Xu, Xiaoling and Du, Yongzhong},
  title = {Sialic Acid‐Functionalized Pyroptosis Nanotuner for Epigenetic Regulation and Enhanced Cancer Immunotherapy},
  journal = {Small},
  year = {2024},
  doi = {10.1002/smll.202306905}
}
Kostenlos starten →